drugset
drugset / Trial / NCT02474901

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

NCT02474901 ↗

Phase 2 Completed 101 enrolled University of Colorado, Denver MedImmune LLC · collab
Non-randomizedParallel-groupOpen-labelHealth-services research

Summary

The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are receiving the quadrivalent live-attenuated influenza vaccine (QLAIV).

Timeline

Start
2013-07
Primary completion
2016-03
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator FluMist® Quadrivalent Vaccine — Intranasal

Indications

HIV infectious disease